Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Insiders at these Companies Have no Fear of Further Turmoil

Page 1 of 2

The U.S. stock markets finished in the green for the second consecutive session, suggesting that the rest of the year might be contending for investors. The Dow Jones Industrial Average closed 235.57 points in the green on Wednesday, while the Standard and Poor’s 500 Index gained slightly below 2%. In fact, all ten sectors in the benchmark closed higher yesterday. It is also worth pointing out that volatility is fading away, as the Chicago Board Options Exchange Volatility Index (VIX) dropped by 8.7% during the last trading session to 24.50. This is all good news for most stock market participants, but the risk of a longer-term downturn should not be overlooked. Even so, many corporate insiders have started to purchase more shares lately, pointing to the fact that some companies may be trading at a discount at the moment. In this article, we will discuss the insider buying activity at three companies: Agenus Inc. (NASDAQ:AGEN), Triangle Capital Corporation (NYSE:TCAP), and Southern Copper Corp. (NYSE:SCCO). Precisely, we will attempt to find out what might have driven these insiders to acquire shares, and possibly pinpoint some trading opportunities.

Most investors can’t outperform the stock market by individually picking stocks because stock returns aren’t evenly distributed. A randomly picked stock has only a 35% to 45% chance (depending on the investment horizon) to outperform the market. There are a few exceptions, one of which is when it comes to purchases made by corporate insiders. Academic research has shown that certain insider purchases historically outperformed the market by an average of seven percentage points per year. This effect is more pronounced in small-cap stocks. Another exception is the small-cap stock picks of hedge funds. Our research has shown that the 15 most popular small-cap stocks among hedge funds outperformed the market by nearly a percentage point per month between 1999 and 2012. We have been forward testing the performance of these stock picks since the end of August 2012 and they have returned more than 118% over the ensuing 36 months, outperforming the S&P 500 Index by nearly 61 percentage points (read the details here). The trick is focusing only on the best small-cap stock picks of funds, not their large-cap stock picks which are extensively covered by analysts and followed by almost everybody.

Let’s begin our discussion by looking into the insider activity at Agenus Inc. (NASDAQ:AGEN). Garo H. Armen, Chairman and Chief Executive Officer, acquired 100,000 shares at a price of $5.03 per unit last Friday, boosting his stake to 1.41 million shares. The executive also owns 300,000 shares indirectly through a trust and 4,046 shares through Antigenics Holdings LLC, where he also serves as Chairman. At the same time, Chief Financial Officer Charles Evan Ballantyne reported purchasing a 10,000 share-stake on the same day for $5.05 per share. The shares of the immunotherapy company have been on a downfall over the past few months, after delivering a return of over 130% through mid-July. The recent sell-off in the biotech industry, caused by worries about political pressures on drug prices, has also hit the stock even more. However, the decline has not been propelled by any firm-specific catalysts, suggesting that the stock is highly likely to bounce back in the months ahead. Peter Kolchinsky’s RA Capital Management, a healthcare-focused investor, initiated a 1.6 million-share position in Agenus Inc. (NASDAQ:AGEN) during the June quarter.

Follow Agenus Inc (NASDAQ:AGEN)
Trade (NASDAQ:AGEN) Now!
Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!